Compare PCRX & APOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | APOG |
|---|---|---|
| Founded | 2006 | 1949 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.0M | 810.1M |
| IPO Year | 2010 | 1994 |
| Metric | PCRX | APOG |
|---|---|---|
| Price | $25.41 | $43.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $30.25 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 642.3K | 171.4K |
| Earning Date | 04-30-2026 | 04-24-2026 |
| Dividend Yield | N/A | ★ 3.03% |
| EPS Growth | ★ 107.44 | N/A |
| EPS | 0.19 | ★ 0.54 |
| Revenue | $541,533,000.00 | ★ $1,404,733,000.00 |
| Revenue This Year | $6.78 | N/A |
| Revenue Next Year | $8.54 | $2.07 |
| P/E Ratio | $131.68 | ★ $80.59 |
| Revenue Growth | ★ 26.04 | 3.21 |
| 52 Week Low | $18.80 | $30.75 |
| 52 Week High | $27.66 | $50.88 |
| Indicator | PCRX | APOG |
|---|---|---|
| Relative Strength Index (RSI) | 44.73 | 59.82 |
| Support Level | $24.61 | $37.04 |
| Resistance Level | $26.94 | $43.36 |
| Average True Range (ATR) | 1.00 | 1.14 |
| MACD | -0.25 | 0.31 |
| Stochastic Oscillator | 18.84 | 80.87 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company geographically operates in the United States, Canada, and Brazil, with the majority revenue generated from the United States.